Alopecia Universalis After Alemtuzumab Treatment for Multiple Sclerosis: A Two-Year Follow-Up of Two Patients
Studysummary This study reports two cases of Alopecia Universalis as a secondary autoimmune manifestation following Alemtuzumab treatment, highlighting the importance of screening and monitoring for such autoimmune responses.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on mdpi.com →